Immunosuppression Withdrawal in Patients with Lupus Nephritis: When, How, and for Whom Will It Be Safe?
作者信息
Frangou Eleni, Anders Hans-Joachim, Bajema Ingeborg M, Teng Y K Onno, Malvar Ana, Rovin Brad H, Kronbichler Andreas
机构信息
Department of Nephrology, Limassol General Hospital, State Health Services Organization, Limassol, Cyprus.
Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.
出版信息
J Am Soc Nephrol. 2024 Jul 1;35(7):955-958. doi: 10.1681/ASN.0000000000000365. Epub 2024 Apr 9.
Abstract
摘要
相似文献
1
Immunosuppression Withdrawal in Patients with Lupus Nephritis: When, How, and for Whom Will It Be Safe?狼疮性肾炎患者免疫抑制治疗的撤减：何时、如何以及对哪些患者而言是安全的？
J Am Soc Nephrol. 2024 Jul 1;35(7):955-958. doi: 10.1681/ASN.0000000000000365. Epub 2024 Apr 9.
2
Immunosuppressive treatment for proliferative lupus nephritis.增殖性狼疮性肾炎的免疫抑制治疗
Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4.
3
Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis.免疫抑制药物和糖皮质激素治疗狼疮性肾炎时发生严重感染的风险：一项系统评价和网状Meta分析
BMC Med. 2016 Sep 13;14(1):137. doi: 10.1186/s12916-016-0673-8.
4
Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis.免疫抑制药物和皮质类固醇治疗狼疮性肾炎的比较疗效：一项系统评价和网状Meta分析。
Syst Rev. 2016 Sep 13;5(1):155. doi: 10.1186/s13643-016-0328-z.
5
Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?狼疮性肾炎：严重狼疮性肾炎的诱导治疗——MMF 是否应被视为首选药物？
Clin J Am Soc Nephrol. 2013 Jan;8(1):147-53. doi: 10.2215/CJN.03290412. Epub 2012 Aug 9.
6
Treatment for lupus nephritis.狼疮性肾炎的治疗。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD002922. doi: 10.1002/14651858.CD002922.pub3.
7
Tacrolimus use in lupus nephritis: A systematic review and meta-analysis.他克莫司在狼疮肾炎中的应用：系统评价和荟萃分析。
Autoimmun Rev. 2016 Jan;15(1):93-101. doi: 10.1016/j.autrev.2015.09.006. Epub 2015 Sep 30.
8
Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical Trial.米唑立宾或环磷酰胺治疗狼疮性肾炎：一项随机临床试验。
JAMA Netw Open. 2025 Mar 3;8(3):e250648. doi: 10.1001/jamanetworkopen.2025.0648.
9
Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.霉酚酸酯用于狼疮性肾炎诱导治疗的系统评价和荟萃分析。
Clin J Am Soc Nephrol. 2007 Sep;2(5):968-75. doi: 10.2215/CJN.01200307. Epub 2007 Aug 8.
10
Fatal visceral disseminated varicella zoster virus infection during initial remission induction therapy in a patient with lupus nephritis: a case report and review of the literature.狼疮性肾炎患者初始缓解诱导治疗期间发生致命性内脏播散性水痘-带状疱疹病毒感染：1例病例报告并文献复习
CEN Case Rep. 2025 Jun;14(3):477-485. doi: 10.1007/s13730-024-00950-7. Epub 2024 Dec 12.
引用本文的文献
1
Immune characterization of lupus nephritis patients undergoing dialysis.接受透析的狼疮性肾炎患者的免疫特征
J Transl Autoimmun. 2025 May 2;10:100290. doi: 10.1016/j.jtauto.2025.100290. eCollection 2025 Jun.
2
Incomplete concordance between laboratory and pathologic findings on post-induction kidney biopsy in pediatric patients with proliferative lupus nephritis.小儿增殖性狼疮性肾炎诱导治疗后肾脏活检的实验室检查结果与病理检查结果不完全一致。
Pediatr Nephrol. 2025 Mar 25. doi: 10.1007/s00467-025-06736-y.
3
Predictive value of residual active histologic lesions on renal flare in lupus nephritis patients with clinical remission.残余活动性组织学病变对临床缓解的狼疮性肾炎患者肾脏复发的预测价值。
Clin Kidney J. 2024 Nov 18;17(12):sfae350. doi: 10.1093/ckj/sfae350. eCollection 2024 Dec.
4
An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes.关于与肾病综合征相关疾病的最新综合综述
Biomedicines. 2024 Oct 4;12(10):2259. doi: 10.3390/biomedicines12102259.
本文引用的文献
1
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.KDIGO 2024狼疮性肾炎管理临床实践指南。
Kidney Int. 2024 Jan;105(1S):S1-S69. doi: 10.1016/j.kint.2023.09.002.
2
Remission of lupus nephritis: the trajectory of histological response in successfully treated patients.狼疮肾炎的缓解：成功治疗患者的组织学反应轨迹。
Lupus Sci Med. 2023 May;10(1). doi: 10.1136/lupus-2023-000932.
3
Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment.狼疮性肾炎临床肾脏缓解后进行肾活检：为评估肾脏预后铺平道路。
Clin Kidney J. 2022 Jun 22;15(11):2081-2088. doi: 10.1093/ckj/sfac150. eCollection 2022 Nov.
4
The influence of repeated flares in response to therapy and prognosis in lupus nephritis.狼疮性肾炎中反复复发对治疗反应及预后的影响。
Nephrol Dial Transplant. 2023 Mar 31;38(4):884-893. doi: 10.1093/ndt/gfac304.
5
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.狼疮肾炎维持性免疫抑制治疗的撤药（WIN-Lupus）：一项多中心随机对照试验的结果。
Ann Rheum Dis. 2022 Oct;81(10):1420-1427. doi: 10.1136/annrheumdis-2022-222435. Epub 2022 Jun 20.
6
Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis.协议规定的重复肾活检预示着增生性狼疮性肾炎的发病病例复发和长期预后不良。
Rheumatology (Oxford). 2020 Nov 1;59(11):3424-3434. doi: 10.1093/rheumatology/keaa129.
7
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.2019 年更新版欧洲抗风湿病联盟与欧洲肾脏学会-欧洲透析和移植学会（EULAR/ERA-EDTA）狼疮肾炎管理建议。
Ann Rheum Dis. 2020 Jun;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27.
8
Lupus nephritis.狼疮性肾炎。
Nat Rev Dis Primers. 2020 Jan 23;6(1):7. doi: 10.1038/s41572-019-0141-9.
9
Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.基于肾活检的维持性免疫抑制治疗管理是安全的，可能改善狼疮肾炎的发作率。
Kidney Int. 2020 Jan;97(1):156-162. doi: 10.1016/j.kint.2019.07.018. Epub 2019 Aug 20.
10
A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.一项前瞻性观察性队列研究强调了维持治疗停药后出现复发的狼疮肾炎缓解患者的肾活检结果。
Kidney Int. 2018 Oct;94(4):788-794. doi: 10.1016/j.kint.2018.05.021. Epub 2018 Jul 23.
Zotero 插件